Trial Profile
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (≥6 To <18 Years of Age)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Etanercept
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms PROTOSTAR
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Dec 2023 Planned End Date changed from 2 Jun 2025 to 18 Dec 2026.
- 05 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2023 Planned primary completion date changed from 8 May 2023 to 19 Jul 2023.